top of page
Update on MedMira’s Reveal® TP (Syphilis) Clinical Trials in Canada
Halifax, Nova Scotia, 14 March, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve regulatory...
MedMira
Mar 14, 20233 min read
MedMira enters into Partnership with Maternova for USA and Latin America
Halifax, Nova Scotia, 20 Februrary, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the singing of a multinational...
MedMira
Feb 20, 20233 min read
Public Information
The Company planned to issue a Press Release with a commercial update this month. Due to a highly positive change in the commercial...
MedMira
Jan 31, 20231 min read
MedMira receives CE mark for its VYRAâ„¢ CoV2Flu Antigen Test
Halifax, Nova Scotia, 11 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™...
MedMira
Jan 11, 20233 min read
MedMira's G4 HIV (FDA approved) rapid test - an independent evaluation by the CDC
Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens...
MedMira
Jan 5, 20231 min read
Point-of-Care Diagnostic for Trichomonas vaginalis based on MedMira’s RVF Technology®
Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic...
MedMira
Jan 3, 20234 min read
bottom of page